Antibiotics: RECARBRIO vs. PIP/TAZ Phase 3 clinical trial results
by Press Release from Outbreak News Today on (#5340P)
Merck announced results from RESTORE-IMI 2, a randomized, controlled, double-blind Phase 3 clinical trial evaluating RECARBRIOTM (imipenem, cilastatin, and relebactam) for the treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP). The results demonstrated noninferiority of RECARBRIO compared to piperacillin and tazobactam (PIP/TAZ), the active comparator, in the primary and key secondary endpoints of the [...]
The post Antibiotics: RECARBRIO vs. PIP/TAZ Phase 3 clinical trial results appeared first on Outbreak News Today.